

## FOSAVANCE® 70 mg/ 5600 IU TABLETS (alendronate sodium/cholecalciferol)

### 1 THERAPEUTIC INDICATIONS AND USAGE

FOSAVANCE® 70 mg/ 5600 IU TABLETS are indicated for:

#### 1.1 Treatment of Osteoporosis in Postmenopausal Women

For the treatment of osteoporosis, FOSAVANCE 70 MG/ 5600 IU TABLETS increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures).

#### Treatment to Increase Bone Mass in Men with Osteoporosis

FOSAVANCE 70 MG/ 5600 IU TABLETS is indicated for treatment to increase bone mass in men with osteoporosis [see *Clinical Studies (14.2)*].

#### 1.2 Important Limitations of Use

FOSAVANCE 70 MG/ 5600 IU TABLETS alone should not be used to treat vitamin D deficiency.

The optimal duration of use has not been determined. The safety and effectiveness of FOSAVANCE 70 MG/ 5600 IU TABLETS for the treatment of osteoporosis are based on clinical data of four years duration. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.

### 2 DOSAGE AND ADMINISTRATION

#### 2.1 Treatment of Osteoporosis in Postmenopausal Women

The recommended dosage is one 70 mg alendronate/5600 IU vitamin D<sub>3</sub> tablet once weekly.

#### 2.2 Treatment to Increase Bone Mass in Men with Osteoporosis

The recommended dosage is one 70 mg alendronate/5600 IU vitamin D<sub>3</sub> tablet once weekly.

#### 2.3 Important Administration Instructions

Instruct patients to do the following:

- Take FOSAVANCE 70 MG/ 5600 IU TABLETS *at least* one-half hour before the first food, beverage, or medication of the day with plain water only [see *Patient Counseling Information (17.2)*]. Other beverages (including mineral water), food, and some medications are likely to reduce the absorption of alendronate [see *Drug Interactions (7.1)*]. Waiting less than 30 minutes, or taking FOSAVANCE 70 MG/ 5600 IU TABLETS with food, beverages (other than plain water) or other medications will lessen the effect of alendronate by decreasing its absorption into the body.
- Take FOSAVANCE 70 MG/ 5600 IU TABLETS upon arising for the day. To facilitate delivery to the stomach and thus reduce the potential for esophageal irritation, FOSAVANCE 70 MG/ 5600 IU TABLETS should be swallowed with a full glass of water ( not less than 200 ml). Patients should not lie down for at least 30 minutes and until after their first food of the day. FOSAVANCE 70 MG/ 5600 IU TABLETS should not be taken at bedtime or before arising for the day. Failure to follow these instructions may increase the risk of esophageal adverse experiences [see *Warnings and Precautions (5.1)* and *Patient Counseling Information (17.2)*].

#### 2.4 Recommendations for Calcium and Vitamin D Supplementation

Instruct patients to take supplemental calcium if dietary intake is inadequate [see *Warnings and Precautions (5.2)*]. Patients at increased risk for vitamin D insufficiency (e.g., over the age of 70 years, nursing home bound, or chronically ill) may need additional vitamin D supplementation. Patients with gastrointestinal malabsorption syndromes may require higher doses of vitamin D supplementation and measurement of 25-hydroxyvitamin D should be considered.

The recommended intake of vitamin D is 400 IU-800 IU daily. FOSAVANCE 70 MG/ 5600 IU TABLETS are intended to provide seven days' worth of 800 IU daily vitamin D in a single, once-weekly dose.

#### 2.5 Administration Instructions for Missed Doses

If a once-weekly dose of FOSAVANCE 70 MG/ 5600 IU TABLETS is missed, instruct patients to take one tablet on the morning after they remember. They should not take two tablets on the same day but should return to taking one tablet once a week, as originally scheduled on their chosen day.

### 3 DOSAGE FORMS AND STRENGTHS

70 mg/5600 IU tablets are white to off-white, modified rectangle-shaped tablets with code 270 on one side and an outline of a bone image on the other.

### 4 CONTRAINDICATIONS

FOSAVANCE 70 MG/ 5600 IU TABLETS is contraindicated in patients with the following conditions:

- Hypersensitivity to the active substances or to any of the excipients listed in section 11. Hypersensitivity reactions including urticaria and angioedema have been reported [see *Adverse Reactions (6.2)*].
- Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia [see *Warnings and Precautions (5.1)*]
- Inability to stand or sit upright for at least 30 minutes [see *Dosage and Administration (2.3)*, *Warnings and Precautions (5.1)*]
- Hypocalcemia [see *Warnings and Precautions (5.2)*]

### 5 WARNINGS AND PRECAUTIONS

#### 5.1 Upper Gastrointestinal Adverse Reactions

FOSAVANCE 70 MG/ 5600 IU TABLETS, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. Because of these possible irritant effects and a potential for worsening of the underlying disease, caution should be used when FOSAVANCE 70 MG/ 5600 IU TABLETS are given to patients with active upper gastrointestinal problems (such as known Barrett's esophagus, dysphagia, other esophageal diseases, gastritis, duodenitis, or ulcers).

Esophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, occasionally with bleeding and rarely followed by esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates including FOSAVANCE 70 MG/ 5600 IU TABLETS. In some cases these have been severe and required hospitalization. Physicians should therefore be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be instructed to discontinue FOSAVANCE 70 MG/ 5600 IU TABLETS and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn.

The risk of severe esophageal adverse experiences appears to be greater in patients who lie down after taking oral bisphosphonates including FOSAVANCE 70 MG/ 5600 IU TABLETS and/or who fail to swallow oral bisphosphonates including FOSAVANCE 70 MG/ 5600 IU TABLETS with the recommended full glass ( not less than 200 ml) of water, and/or who continue to take oral bisphosphonates including FOSAVANCE 70 MG/ 5600 IU TABLETS after developing symptoms suggestive of esophageal irritation. Therefore, it is very important that the full dosing instructions are provided to, and understood by, the patient [see *Dosage and Administration (2.3)*]. In patients who cannot comply with dosing instructions due to mental disability, therapy with FOSAVANCE 70 MG/ 5600 IU TABLETS should be used under appropriate supervision.

There have been post-marketing reports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications, although no increased risk was observed in controlled clinical trials [see *Adverse Reactions (6.2)*].

#### 5.2 Mineral Metabolism

##### *Alendronate Sodium*

Hypocalcemia must be corrected before initiating therapy with FOSAVANCE 70 MG/ 5600 IU TABLETS [see *Contraindications (4)*]. Other disorders affecting mineral metabolism (such as vitamin D deficiency) should also be effectively treated. In patients with these conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with FOSAVANCE 70 MG/ 5600 IU TABLETS

Presumably due to the effects of alendronate on increasing bone mineral, small, asymptomatic decreases in serum calcium and phosphate may occur.

##### *Cholecalciferol*

FOSAVANCE 70 MG/ 5600 IU TABLETS alone should not be used to treat vitamin D deficiency (commonly defined as 25-hydroxyvitamin D level below 9 ng/mL). Patients at increased risk for vitamin D insufficiency may require higher doses of vitamin D supplementation [see *Dosage and Administration*

(2.4)]. Patients with gastrointestinal malabsorption syndromes may require higher doses of vitamin D supplementation and measurement of 25-hydroxyvitamin D should be considered.

Vitamin D<sub>3</sub> supplementation may worsen hypercalcemia and/or hypercalciuria when administered to patients with diseases associated with unregulated overproduction of 1,25 dihydroxyvitamin D (e.g., leukemia, lymphoma, sarcoidosis). Urine and serum calcium should be monitored in these patients.

### **5.3 Musculoskeletal Pain**

In post-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported in patients taking bisphosphonates that are approved for the prevention and treatment of osteoporosis [see *Adverse Reactions (6.2)*]. This category of drugs includes alendronate. Most of the patients were postmenopausal women. The time to onset of symptoms varied from one day to several months after starting the drug. Discontinue use if severe symptoms develop. Most patients had relief of symptoms after stopping. A subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate.

In placebo-controlled clinical studies of FOSALAN, the percentages of patients with these symptoms were similar in the FOSALAN and placebo groups.

### **5.4 Osteonecrosis of the Jaw**

Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including FOSAVANCE 70 MG/ 5600 IU TABLETS. Known risk factors for osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, bone surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) and smoking. The risk of ONJ may increase with duration of exposure to bisphosphonates.

For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ. Clinical judgment of the treating physician and/or oral surgeon should guide the management plan of each patient based on individual benefit/risk assessment.

Patients who develop osteonecrosis of the jaw while on bisphosphonate therapy should receive care by an oral surgeon. In these patients, extensive dental surgery to treat ONJ may exacerbate the condition. Discontinuation of bisphosphonate therapy should be considered based on individual benefit/risk assessment.

### **5.5 Osteonecrosis of the external auditory canal**

Osteonecrosis of the external auditory canal has been reported with bisphosphonates, mainly in association with long-term therapy. Possible risk factors for osteonecrosis of the external auditory canal include steroid use and chemotherapy and/or local risk factors such as infection or trauma. The possibility of osteonecrosis of the external auditory canal should be considered in patients receiving bisphosphonates who present with ear symptoms such as pain or discharge, or chronic ear infections.

### **5.6 Atypical Subtrochanteric and Diaphyseal Femoral Fractures**

Atypical, low-energy, or low trauma fractures of the femoral shaft have been reported in bisphosphonate-treated patients. These fractures can occur anywhere in the femoral shaft from just below the lesser trochanter to above the supracondylar flare and are transverse or short oblique in orientation without evidence of comminution. Causality has not been established as these fractures also occur in osteoporotic patients who have not been treated with bisphosphonates.

Atypical femur fractures most commonly occur with minimal or no trauma to the affected area. They may be bilateral and many patients report prodromal pain in the affected area, usually presenting as dull, aching thigh pain, weeks to months before a complete fracture occurs. A number of reports note that patients were also receiving treatment with glucocorticoids (e.g. prednisone) at the time of fracture.

Any patient with a history of bisphosphonate exposure who presents with thigh or groin pain should be suspected of having an atypical fracture and should be evaluated to rule out an incomplete femur fracture. Patients presenting with an atypical fracture should also be assessed for symptoms and signs of fracture in the contralateral limb. Interruption of bisphosphonate therapy should be considered, pending a risk/benefit assessment, on an individual basis.

## 5.7 Renal Impairment

FOSAVANCE 70 MG/ 5600 IU TABLETS are not recommended for patients with creatinine clearance less than 35 mL/min).

## 6 ADVERSE REACTIONS

### 6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

#### FOSALAN

##### Treatment of Osteoporosis in Postmenopausal Women

##### FOSALAN daily

The safety of FOSALAN in the treatment of postmenopausal osteoporosis was assessed in four clinical trials that enrolled 7453 women aged 44-84 years. Study 1 and Study 2 were identically designed, three-year, placebo-controlled, double-blind, multicenter studies (United States and Multinational; n=994); Study 3 was the three-year vertebral fracture cohort of the Fracture Intervention Trial [FIT] (n=2027); and Study 4 was the four-year clinical fracture cohort of FIT (n=4432). Overall, 3620 patients were exposed to placebo and 3432 patients exposed to FOSALAN. Patients with pre-existing gastrointestinal disease and concomitant use of non-steroidal anti-inflammatory drugs were included in these clinical trials. In Study 1 and Study 2 all women received 500 mg elemental calcium as carbonate. In Study 3 and Study 4 all women with dietary calcium intake less than 1000 mg per day received 500 mg calcium and 250 international units Vitamin D per day.

Among patients treated with alendronate 10 mg or placebo in Study 1 and Study 2, and all patients in Study 3 and Study 4, the incidence of all-cause mortality was 1.8% in the placebo group and 1.8% in the FOSALAN group. The incidence of serious adverse event was 30.7% in the placebo group and 30.9% in the FOSALAN group. The percentage of patients who discontinued the study due to any clinical adverse event was 9.5% in the placebo group and 8.9% in the FOSALAN group. Adverse reactions from these studies considered by the investigators as possibly, probably, or definitely drug related in greater than or equal to 1% of patients treated with either FOSALAN or placebo are presented in Table 1.

	United States/Multinational Studies		Fracture Intervention Trial	
	FOSALAN <sup>*</sup> % (n=196)	Placebo % (n=397)	FOSALAN <sup>†</sup> % (n=3236)	Placebo % (n=3223)
<i>Gastrointestinal</i>				
abdominal pain	6.6	4.8	1.5	1.5
nausea	3.6	4.0	1.1	1.5
dyspepsia	3.6	3.5	1.1	1.2
constipation	3.1	1.8	0.0	0.2
diarrhea	3.1	1.8	0.6	0.3
flatulence	2.6	0.5	0.2	0.3
acid regurgitation	2.0	4.3	1.1	0.9
esophageal ulcer	1.5	0.0	0.1	0.1
vomiting	1.0	1.5	0.2	0.3
dysphagia	1.0	0.0	0.1	0.1
abdominal distention	1.0	0.8	0.0	0.0
gastritis	0.5	1.3	0.6	0.7
<i>Musculoskeletal</i>				
musculoskeletal (bone, muscle or joint) pain	4.1	2.5	0.4	0.3
muscle cramp	0.0	1.0	0.2	0.1
<i>Nervous System/Psychiatric</i>				
headache	2.6	1.5	0.2	0.2
dizziness	0.0	1.0	0.0	0.1
<i>Special Senses</i>				
taste perversion	0.5	1.0	0.1	0.0

<sup>\*</sup> 10 mg/day for three years

<sup>†</sup> 5 mg/day for 2 years and 10 mg/day for either 1 or 2 additional years

Rash and erythema have occurred.

**Gastrointestinal Adverse Reactions:** One patient treated with FOSALAN (10 mg/day), who had a history of peptic ulcer disease and gastrectomy and who was taking concomitant aspirin, developed an anastomotic ulcer with mild hemorrhage, which was considered drug related. Aspirin and FOSALAN were discontinued and the patient recovered. In the Study 1 and Study 2 populations, 49-54% had a history of gastrointestinal disorders at baseline, and 54-89% used nonsteroidal anti-inflammatory drugs or aspirin at some time during the studies. [See *Warnings and Precautions (5.1).*]

**Laboratory Test Findings:** In double-blind, multicenter, controlled studies, asymptomatic, mild, and transient decreases in serum calcium and phosphate were observed in approximately 18% and 10%, respectively, of patients taking FOSALAN versus approximately 12% and 3% of those taking placebo. However, the incidences of decreases in serum calcium to less than 8.0 mg/dL (2.0 mM) and serum phosphate to less than or equal to 2.0 mg/dL (0.65 mM) were similar in both treatment groups.

**FOSALAN Once-Weekly 70 mg**

The safety of FOSALAN Once-Weekly 70 mg for the treatment of postmenopausal osteoporosis was assessed in a one-year, double-blind, multicenter study comparing FOSALAN Once-Weekly 70 mg and FOSALAN 10 mg daily. The overall safety and tolerability profiles of FOSALAN Once-Weekly 70 mg and FOSALAN 10 mg daily were similar. The adverse reactions considered by the investigators as possibly, probably, or definitely drug related in greater than or equal to 1% of patients in either treatment group are presented in Table 2.

**Table 2: Osteoporosis Treatment Studies in Postmenopausal Women  
Adverse Reactions Considered Possibly, Probably, or Definitely Drug Related  
by the Investigators and Reported in Greater Than or Equal to 1% of Patients**

	FOSALAN Once-Weekly 70 mg % (n=519)	FOSALAN 10 mg/day % (n=370)
<i>Gastrointestinal</i>		
abdominal pain	3.7	3.0
dyspepsia	2.7	2.2
acid regurgitation	1.9	2.4
nausea	1.9	2.4
abdominal distention	1.0	1.4
constipation	0.8	1.6
flatulence	0.4	1.6
gastritis	0.2	1.1
gastric ulcer	0.0	1.1
<i>Musculoskeletal</i>		
musculoskeletal (bone, muscle, joint) pain	2.9	3.2
muscle cramp	0.2	1.1

**Concomitant Use With Estrogen/Hormone Replacement Therapy**

In two studies (of one and two years' duration) of postmenopausal osteoporotic women (total: n=853), the safety and tolerability profile of combined treatment with FOSALAN 10 mg once daily and estrogen ± progestin (n=354) was consistent with those of the individual treatments.

**Osteoporosis in Men**

In two placebo-controlled, double-blind, multicenter studies in men (a two-year study of FOSALAN 10 mg/day and a one-year study of FOSALAN Once-Weekly 70 mg) the rates of discontinuation of therapy due to any clinical adverse event were 2.7% for FOSALAN 10 mg/day vs. 10.5% for placebo, and 6.4% for once weekly FOSALAN Once-Weekly 70 mg vs. 8.6% for placebo. The adverse reactions considered by the investigators as possibly, probably, or definitely drug related in greater than or equal to 2% of patients treated with either FOSALAN or placebo are presented in Table 3.



**Table 3: Osteoporosis Studies in Men  
Adverse Reactions Considered Possibly, Probably, or  
Definitely Drug Related by the Investigators and  
Reported in Greater Than or Equal to 2% of Patients**

	Two-year Study		One-year Study	
	FOSALAN 10 mg/day % (n=146)	Placebo % (n=95)	FOSALAN Once-Weekly 70 mg % (n=109)	Placebo % (n=58)
<i>Gastrointestinal</i>				
acid regurgitation	4.1	3.2	0.0	0.0
flatulence	4.1	1.1	0.0	0.0
gastroesophageal reflux disease	0.7	3.2	2.8	0.0
dyspepsia	3.4	0.0	2.8	1.7
diarrhea	1.4	1.1	2.8	0.0
abdominal pain	2.1	1.1	0.9	3.4
nausea	2.1	0.0	0.0	0.0

## FOSAVANCE

In a fifteen-week double-blind, multinational study in osteoporotic postmenopausal women (n=682) and men (n=35), the safety profile of FOSAVANCE (70 mg/2800 IU) was similar to that of FOSALAN once weekly 70 mg. In the 24-week double-blind extension study in women (n=619) and men (n=33), the safety profile of FOSAVANCE (70 mg/2800 IU) administered with an additional 2800 IU vitamin D<sub>3</sub> was similar to that of FOSAVANCE (70 mg/2800 IU).

### 6.2 Post-Marketing Experience

The following adverse reactions have been identified during post-approval use of FOSALAN and FOSAVANCE 70 mg/ 5600 IU TABLETS. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

*Body as a Whole:* hypersensitivity reactions including urticaria and angioedema. Transient symptoms of myalgia, malaise, asthenia and rarely, fever have been reported with alendronate, typically in association with initiation of treatment. Symptomatic hypocalcemia has occurred, generally in association with predisposing conditions. Peripheral edema.

*Gastrointestinal:* esophagitis, esophageal erosions, esophageal ulcers, esophageal stricture or perforation, and oropharyngeal ulceration. Gastric or duodenal ulcers, some severe and with complications have also been reported [see *Dosage and Administration (2.3) and Warnings and Precautions (5.1)*].

Localized osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection with delayed healing, has been reported [see *Warnings and Precautions (5.4)*].

*Musculoskeletal:* bone, joint, and/or muscle pain, occasionally severe, and incapacitating [see *Warnings and Precautions (5.3)*]; joint swelling; low-energy femoral shaft and subtrochanteric fractures [see *Warnings and Precautions (5.5)*].

*Nervous System:* dizziness and vertigo.

*Pulmonary:* acute asthma exacerbations.

*Skin:* rash (occasionally with photosensitivity), pruritus, alopecia, severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.

*Special Senses:* uveitis, scleritis or episcleritis. Very rare: Osteonecrosis of the external auditory canal (bisphosphonate class adverse reaction).

#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form <https://sideeffects.health.gov.il>

### 6.3 Driving and using machines

FOSAVANCE may have a moderate influence on the ability to drive and use machines in patients that experience certain adverse reactions (for example blurred vision, dizziness and severe bone muscle or joint pain).

## 7 DRUG INTERACTIONS

### 7.1 Calcium Supplements/Antacids

Co-administration of FOSAVANCE 70 mg/ 5600 IU TABLETS and calcium, antacids, or oral medications containing multivalent cations will interfere with absorption of alendronate. Therefore, patients to wait at least one-half hour after taking FOSAVANCE 70 mg/ 5600 IU TABLETS before taking any other oral medications.

### 7.2 Aspirin

In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving concomitant therapy with daily doses of FOSALAN greater than 10 mg and aspirin-containing products.

### 7.3 Nonsteroidal Anti-Inflammatory Drugs

FOSAVANCE 70 mg/ 5600 IU TABLETS may be administered to patients taking nonsteroidal anti-inflammatory drugs (NSAIDs). In a 3-year, controlled, clinical study (n=2027) during which a majority of patients received concomitant NSAIDs, the incidence of upper gastrointestinal adverse events was similar in patients taking FOSALAN 5 or 10 mg/day compared to those taking placebo. However, since NSAID use is associated with gastrointestinal irritation, caution should be used during concomitant use with FOSAVANCE 70 mg/ 5600 IU TABLETS.

### 7.4 Drugs that May Impair the Absorption of Cholecalciferol

Olestra, mineral oils, orlistat, and bile acid sequestrants (e.g., cholestyramine, colestipol) may impair the absorption of vitamin D. Additional vitamin D supplementation should be considered [see *Clinical Pharmacology* (12.3)].

### 7.5 Drugs that May Increase the Catabolism of Cholecalciferol

Anticonvulsants, cimetidine, and thiazides may increase the catabolism of vitamin D. Additional vitamin D supplementation should be considered [see *Clinical Pharmacology* (12.3)].

## 8 USE IN SPECIFIC POPULATIONS

### 8.1 Pregnancy

#### *Risk Summary*

Available data on the use of FOSAVANCE 70 MG/ 5600 IU TABLETS use in pregnant women are insufficient to inform a drug-associated risk of adverse maternal or fetal outcomes. Discontinue FOSAVANCE 70 MG/ 5600 IU TABLETS when pregnancy is recognized.

#### *Alendronate Sodium*

In animal reproduction studies, daily oral administration of alendronate to rats from before mating through the end of gestation or lactation showed decreased postimplantation survival and decreased pup body weight gain starting at doses equivalent to less than half of the highest recommended 40 mg clinical daily dose (based on body surface area, mg/m<sup>2</sup>). Oral administration of alendronate to rats during organogenesis resulted in reduced fetal ossification starting at doses 3 times the 40 mg clinical daily dose. No similar fetal effects were observed in pregnant rabbits dosed orally during organogenesis at doses equivalent to approximately 10 times the 40 mg clinical daily dose.

Delayed or failed delivery of offspring, protracted parturition, and late pregnancy maternal and fetal deaths due to maternal hypocalcemia occurred in rats at oral doses as low as one tenth the 40 mg clinical daily dose (see *Data*).

Bisphosphonates are incorporated into the bone matrix, from which they are gradually released over a period of years. The amount of bisphosphonate incorporated into adult bone and available for release into the systemic circulation is directly related to the dose and duration of bisphosphonate use. Consequently, based on the mechanism of action of bisphosphonates, there is a potential risk of fetal harm, predominantly skeletal, if a woman becomes pregnant after completing a course of bisphosphonate therapy. The impact of variables such as time between cessation of bisphosphonate therapy to conception, the particular bisphosphonate used, and the route of administration (intravenous versus oral) on the risk has not been studied.

#### *Cholecalciferol*

No data are available for cholecalciferol (vitamin D<sub>3</sub>) in animals. However, administration of high doses of vitamin D<sub>2</sub> to pregnant rabbits resulted in abortions and an increase incidence of fetal aortic stenosis.

Administration of high doses of vitamin D<sub>2</sub> to pregnant rats resulted in neonatal death, decreased fetal weight, and impaired osteogenesis of long bones postnatally.

(See Data.)

The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

*Data*

*Animal Data*

*Alendronate Sodium*

Reproduction studies in rats dosed orally from before mating to the end of gestation or lactation showed decreased postimplantation survival starting at 2 mg/kg/day and decreased body weight gain starting at 1 mg/kg/day, doses equivalent to less than half the 40 mg clinical daily dose based on body surface area, mg/m<sup>2</sup>. Incidence of incomplete fetal ossification in vertebral, skull, and sternebral bones were increased in rats dosed orally during organogenesis starting at 10 mg/kg/day (approximately 3 times the 40 mg clinical daily dose). No similar fetal effects were observed in pregnant rabbits dosed orally during organogenesis at up to 35 mg/kg/day (equivalent to approximately 10 times the 40 mg clinical daily dose).

Both total and ionized calcium decreased in pregnant rats dosed orally with 15 mg/kg/day alendronate (approximately 4 times the 40 mg clinical daily dose) resulting in delays and failures of delivery. Protracted parturition due to maternal hypocalcemia was observed when rats were treated from before mating through gestation starting at 0.5 mg/kg/day (approximately one tenth the 40 mg clinical daily dose). Maternotoxicity (late pregnancy deaths) also occurred in female rats treated orally with 15 mg/kg/day (approximately 4 times the 40 mg clinical daily dose) for varying gestational time periods. These maternal deaths were lessened but not eliminated by cessation of treatment. Calcium supplementation in the drinking water or by subcutaneous minipump to rats dosed orally with 15 mg/kg/day alendronate could not ameliorate the hypocalcemia or prevent the dystocia-related maternal and neonatal deaths. However, intravenous calcium supplementation prevented maternal, but not neonatal deaths.

*Cholecalciferol*

Administration of high doses (greater than 10,000 IU/every other day during pregnancy) of ergocalciferol (vitamin D<sub>2</sub>) to pregnant rabbits resulted in abortions and an increased incidence of fetal aortic stenosis. Administration of vitamin D<sub>2</sub> (40,000 IU /day) to pregnant rats from gestation day 10 to 21 (organogenesis) resulted in neonatal death, decreased fetal weight, and impaired osteogenesis of long bones postnatally.

## **8.2 Lactation**

*Risk Summary*

Cholecalciferol and some of its active metabolites pass into breast milk. It is not known whether alendronate is present in human breast milk, affects human milk production, or has effects on the breastfed infant. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for FOSAVANCE 70 MG/ 5600 IU TABLETS and any potential adverse effects on the breastfed child from FOSAVANCE 70 MG/ 5600 IU TABLETS or from the underlying maternal condition.

## **8.4 Pediatric Use**

FOSAVANCE 70 MG/ 5600 IU TABLETS are not indicated for use in pediatric patients.

The safety and efficacy of alendronate were examined in a randomized, double-blind, placebo-controlled two-year study of 139 pediatric patients, aged 4-18 years, with severe osteogenesis imperfecta (OI). One-hundred-and-nine patients were randomized to 5 mg alendronate daily (weight less than 40 kg) or 10 mg alendronate daily (weight greater than or equal to 40 kg) and 30 patients to placebo. The mean baseline lumbar spine BMD Z-score of the patients was -4.5. The mean change in lumbar spine BMD Z-score from baseline to Month 24 was 1.3 in the alendronate-treated patients and 0.1 in the placebo-treated patients. Treatment with alendronate did not reduce the risk of fracture. Sixteen percent of the alendronate patients who sustained a radiologically-confirmed fracture by Month 12 of the study had delayed fracture healing (callus remodeling) or fracture non-union when assessed radiographically at Month 24 compared with 9% of the placebo-treated patients. In alendronate-treated patients, bone histomorphometry data obtained at Month 24 demonstrated decreased bone turnover and delayed mineralization time; however, there were no mineralization defects. There were no statistically significant differences between the alendronate and placebo groups in reduction of bone pain. The oral bioavailability of alendronate in children was similar to that observed in adults.

## **8.5 Geriatric Use**

Of the patients receiving FOSALAN in the Fracture Intervention Trial (FIT), 71% (n=2302) were greater than or equal to 65 years of age and 17% (n=550) were greater than or equal to 75 years of age. Of the patients receiving FOSALAN in the United States and Multinational osteoporosis treatment studies in



women, and osteoporosis studies in men [see *Clinical Studies (14.1, 14.2)*], 45% and 54%, respectively, were 65 years of age or over. No overall differences in efficacy or safety were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Dietary requirements of vitamin D<sub>3</sub> are increased in the elderly.

### 8.6 Renal Impairment

FOSAVANCE 70 MG/ 5600 IU TABLETS are not recommended for patients with creatinine clearance less than 35 mL/min. No dosage adjustment is necessary in patients with creatinine clearance values between 35-60 mL/min [see *Clinical Pharmacology (12.3)*].

### 8.7 Hepatic Impairment

#### *Alendronate Sodium*

As there is evidence that alendronate is not metabolized or excreted in the bile, no studies were conducted in patients with hepatic impairment. No dosage adjustment is necessary [see *Clinical Pharmacology (12.3)*].

#### *Cholecalciferol*

Vitamin D<sub>3</sub> may not be adequately absorbed in patients who have malabsorption due to inadequate bile production.

## 10 OVERDOSAGE

#### *Alendronate Sodium*

Significant lethality after single oral doses with alendronate was seen in female rats and mice at 552 mg/kg (3256 mg/m<sup>2</sup>) and 966 mg/kg (2898 mg/m<sup>2</sup>), respectively. In males, these values were slightly higher, 626 and 1280 mg/kg, respectively.

There was no lethality in dogs at oral doses up to 200 mg/kg (4000 mg/m<sup>2</sup>).

No specific information is available on the treatment of overdosage with alendronate. Hypocalcemia, hypophosphatemia, and upper gastrointestinal adverse events, such as upset stomach, heartburn, esophagitis, gastritis, or ulcer, may result from oral overdosage. Milk or antacids should be given to bind alendronate. Due to the risk of esophageal irritation, vomiting should not be induced and the patient should remain fully upright.

Dialysis would not be beneficial.

#### *Cholecalciferol*

Significant lethality occurred in mice treated with a single high oral dose of calcitriol (4 mg/kg), the hormonal metabolite of cholecalciferol.

There is limited information regarding doses of cholecalciferol associated with acute toxicity, although intermittent (yearly or twice yearly) single doses of ergocalciferol (vitamin D<sub>2</sub>) as high as 600,000 IU have been given without reports of toxicity. Signs and symptoms of vitamin D toxicity include hypercalcemia, hypercalciuria, anorexia, nausea, vomiting, polyuria, polydipsia, weakness, and lethargy. Serum and urine calcium levels should be monitored in patients with suspected vitamin D toxicity. Standard therapy includes restriction of dietary calcium, hydration, and systemic glucocorticoids in patients with severe hypercalcemia.

Dialysis to remove vitamin D would not be beneficial.

## 11 DESCRIPTION


FOSAVANCE 70 MG/ 5600 IU TABLETS contain alendronate sodium, a bisphosphonate, and cholecalciferol (vitamin D<sub>3</sub>).

Alendronate sodium is a bisphosphonate that acts as a specific inhibitor of osteoclast-mediated bone resorption. Bisphosphonates are synthetic analogs of pyrophosphate that bind to the hydroxyapatite found in bone.

Alendronate sodium is chemically described as (4-amino-1-hydroxybutylidene) bisphosphonic acid monosodium salt trihydrate.

The empirical formula of alendronate sodium is C<sub>4</sub>H<sub>12</sub>NNaO<sub>7</sub>P<sub>2</sub>•3H<sub>2</sub>O and its formula weight is 325.12.


The structural formula is:



Alendronate sodium is a white, crystalline, nonhygroscopic powder. It is soluble in water, very slightly soluble in alcohol, and practically insoluble in chloroform.

Cholecalciferol (vitamin D<sub>3</sub>) is a secosterol that is the natural precursor of the calcium-regulating hormone calcitriol (1,25 dihydroxyvitamin D<sub>3</sub>).

The chemical name of cholecalciferol is (3 $\beta$ ,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol. The empirical formula of cholecalciferol is C<sub>27</sub>H<sub>44</sub>O and its molecular weight is 384.6. The structural formula is:



Cholecalciferol is a white, crystalline, odorless powder. Cholecalciferol is practically insoluble in water, freely soluble in usual organic solvents, and slightly soluble in vegetable oils.

FOSAVANCE 70 MG/ 5600 IU TABLETS for oral administration contains 91.37 mg of alendronate monosodium salt trihydrate, the molar equivalent of 70 mg of free acid, and 140 mcg of cholecalciferol, equivalent to 5600 international units (IU) vitamin D. Each tablet contains the following inactive ingredients: microcrystalline cellulose, lactose anhydrous, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, medium chain triglycerides, butylated hydroxytoluene, sucrose, gelatin, modified food starch, and sodium aluminium silicate.

## 12 CLINICAL PHARMACOLOGY

### 12.1 Mechanism of Action

#### *Alendronate Sodium*

Animal studies have indicated the following mode of action. At the cellular level, alendronate shows preferential localization to sites of bone resorption, specifically under osteoclasts. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of active resorption. Alendronate does not interfere with osteoclast recruitment or attachment, but it does inhibit osteoclast activity. Studies in mice on the localization of radioactive [<sup>3</sup>H]alendronate in bone showed about 10-fold higher uptake on osteoclast surfaces than on osteoblast surfaces. Bones examined 6 and 49 days after [<sup>3</sup>H]alendronate administration in rats and mice, respectively, showed that normal bone was formed on top of the alendronate, which was incorporated inside the matrix. While incorporated in bone matrix, alendronate is not pharmacologically active. Thus, alendronate must be continuously administered to suppress osteoclasts on newly formed resorption surfaces. Histomorphometry in baboons and rats showed that alendronate treatment reduces bone turnover (i.e., the number of sites at which bone is remodeled). In addition, bone formation exceeds bone resorption at these remodeling sites, leading to progressive gains in bone mass.

#### *Cholecalciferol*

Vitamin D<sub>3</sub> is produced in the skin by photochemical conversion of 7-dehydrocholesterol to previtamin D<sub>3</sub> by ultraviolet light. This is followed by non-enzymatic isomerization to vitamin D<sub>3</sub>. In the absence of adequate sunlight exposure, vitamin D<sub>3</sub> is an essential dietary nutrient. Vitamin D<sub>3</sub> in skin and dietary vitamin D<sub>3</sub> (absorbed into chylomicrons) is converted to 25-hydroxyvitamin D<sub>3</sub> in the liver. Conversion to the active calcium-mobilizing hormone 1,25-dihydroxyvitamin D<sub>3</sub> (calcitriol) in the kidney is stimulated by both parathyroid hormone and hypophosphatemia. The principal action of 1,25-dihydroxyvitamin D<sub>3</sub> is to increase intestinal absorption of both calcium and phosphate as well as regulate serum calcium, renal calcium and phosphate excretion, bone formation and bone resorption.

Vitamin D is required for normal bone formation. Vitamin D insufficiency develops when both sunlight exposure and dietary intake are inadequate. Insufficiency is associated with negative calcium balance, increased parathyroid hormone levels, bone loss, and increased risk of skeletal fracture. In severe cases, deficiency results in more severe hyperparathyroidism, hypophosphatemia, proximal muscle weakness, bone pain and osteomalacia.

## 12.2 Pharmacodynamics

### *Alendronate Sodium*

Alendronate is a bisphosphonate that binds to bone hydroxyapatite and specifically inhibits the activity of osteoclasts, the bone-resorbing cells. Alendronate reduces bone resorption with no direct effect on bone formation, although the latter process is ultimately reduced because bone resorption and formation are coupled during bone turnover.

Daily oral doses of alendronate (5, 20, and 40 mg for six weeks) in postmenopausal women produced biochemical changes indicative of dose-dependent inhibition of bone resorption, including decreases in urinary calcium and urinary markers of bone collagen degradation (such as deoxypyridinoline and cross-linked N-telopeptides of type I collagen). These biochemical changes tended to return toward baseline values as early as 3 weeks following the discontinuation of therapy with alendronate and did not differ from placebo after 7 months.

Long-term treatment of osteoporosis with FOSALAN 10 mg/day (for up to five years) reduced urinary excretion of markers of bone resorption, deoxypyridinoline and cross-linked N-telopeptides of type I collagen, by approximately 50% and 70%, respectively, to reach levels similar to those seen in healthy premenopausal women. The decrease in the rate of bone resorption indicated by these markers was evident as early as one month and at three to six months reached a plateau that was maintained for the entire duration of treatment with FOSALAN. In osteoporosis treatment studies FOSALAN 10 mg/day decreased the markers of bone formation, osteocalcin and bone specific alkaline phosphatase by approximately 50%, and total serum alkaline phosphatase by approximately 25 to 30% to reach a plateau after 6 to 12 months. Similar reductions in the rate of bone turnover were observed in postmenopausal women during one-year studies with once weekly FOSALAN 70 mg for the treatment of osteoporosis. These data indicate that the rate of bone turnover reached a new steady-state, despite the progressive increase in the total amount of alendronate deposited within bone.

As a result of inhibition of bone resorption, asymptomatic reductions in serum calcium and phosphate concentrations were also observed following treatment with FOSALAN. In the long-term studies, reductions from baseline in serum calcium (approximately 2%) and phosphate (approximately 4 to 6%) were evident the first month after the initiation of FOSALAN 10 mg. No further decreases in serum calcium were observed for the five-year duration of treatment; however, serum phosphate returned toward prestudy levels during years three through five. In one-year studies with once weekly FOSALAN 70 mg, similar reductions were observed at 6 and 12 months. The reduction in serum phosphate may reflect not only the positive bone mineral balance due to FOSALAN but also a decrease in renal phosphate reabsorption.

### *Osteoporosis in Men*

Treatment of men with osteoporosis with FOSALAN 10 mg/day for two years reduced urinary excretion of cross-linked N-telopeptides of type I collagen by approximately 60% and bone-specific alkaline phosphatase by approximately 40%. Similar reductions were observed in a one-year study in men with osteoporosis receiving once weekly FOSALAN 70 mg.

### *Cholecalciferol*

Vitamin D is required for normal bone formation. Vitamin D insufficiency is associated with negative calcium balance, leading to increased parathyroid hormone levels and worsening of bone loss associated with osteoporosis. When taken without vitamin D, alendronate is also associated with a reduction in serum calcium concentrations and increased parathyroid hormone levels. In a 15-week trial, 717 postmenopausal women and men, mean age 67 years, with osteoporosis (lumbar spine bone mineral density [BMD] of at least 2.5 standard deviations below the premenopausal mean) were randomized to receive either weekly FOSAVANCE 70 mg/2800 IU vitamin D or weekly FOSALAN 70 mg alone with no vitamin D supplementation. Patients who were vitamin D deficient (25-hydroxyvitamin D less than 9 ng/mL) at baseline were excluded. Treatment with FOSAVANCE 70 mg/ 2800 IU resulted in a smaller reduction in serum calcium levels (-0.9%) when compared to FOSALAN 70 mg alone (-1.4%). As well, treatment with FOSAVANCE 70 mg/ 2800 IU resulted in a significantly smaller increase in parathyroid hormone levels when compared to FOSALAN 70 mg alone (14% and 24%, respectively).

The sufficiency of patients' vitamin D status is best assessed by measuring 25-hydroxyvitamin D levels. In the 15-week trial mentioned above, baseline 25-hydroxyvitamin D levels were 22.2 ng/mL in the FOSAVANCE group and 22.1 ng/mL in the FOSALAN only group. After 15 weeks of treatment, the mean levels were 23.1 ng/mL and 18.4 ng/mL in the FOSAVANCE and FOSALAN only groups, respectively. The final levels of 25-hydroxyvitamin D at Week 15 are summarized in Table 4.

Table 4: 25-hydroxyvitamin D Levels after Treatment with FOSAVANCE (70 mg/2800 IU) or FOSALAN 70 mg at Week 15<sup>\*</sup>

25-hydroxyvitamin D Ranges (ng/mL)	Number (%) of Patients					
	<9	9-14	15-19	20-24	25-29	30-62
FOSAVANCE (70 mg/2800 IU) (N=357)	4 (1.1)	37 (10.4)	87 (24.4)	84 (23.5)	82 (23.0)	63 (17.7)
FOSALAN 70 mg (N=351)	46 (13.1)	66 (18.8)	108 (30.8)	58 (16.5)	37 (10.5)	36 (10.3)

<sup>\*</sup> Patients who were vitamin D deficient (25-hydroxyvitamin D less than 9 ng/mL) at baseline were excluded.

Patients (n=652) who completed the above 15-week trial continued in a 24-week extension in which all received FOSAVANCE (70 mg/2800 IU) and were randomly assigned to receive either additional once weekly vitamin D<sub>3</sub> 2800 IU (Vitamin D<sub>3</sub> 5600 IU group) or matching placebo (Vitamin D<sub>3</sub> 2800 IU group). After 24 weeks of extended treatment (Week 39 from original baseline), the mean levels of 25-hydroxyvitamin D were 27.9 ng/mL and 25.6 ng/mL in the vitamin D<sub>3</sub> 5600 IU group and vitamin D<sub>3</sub> 2800 IU group, respectively. The percentage of patients with hypercalciuria at Week 39 was not statistically different between treatment groups.

The distribution of the final levels of 25-hydroxyvitamin D at Week 39 is summarized in Table 5.

Table 5: 25-hydroxyvitamin D Levels after Treatment with FOSAVANCE at Week 39

25-hydroxyvitamin D Ranges (ng/mL)	Number (%) of Patients					
	<9	9-14	15-19	20-24	25-29	30-59
FOSAVANCE (Vitamin D <sub>3</sub> 5600 IU group) <sup>†</sup> (N=321)	0	10 (3.1)	29 (9.0)	79 (24.6)	87 (27.1)	116 (36.1)
FOSAVANCE (Vitamin D <sub>3</sub> 2800 IU group) <sup>†</sup> (N=320)	1 (0.3)	17 (5.3)	56 (17.5)	80 (25.0)	74 (23.1)	92 (28.8)

<sup>\*</sup> Patients received FOSALAN 70 mg or FOSAVANCE (70 mg/2800 IU) for the 15-week base study followed by FOSAVANCE (70 mg/2800 IU) and 2800 IU additional vitamin D<sub>3</sub> for the 24-week extension study.

<sup>†</sup> Patients received FOSALAN 70 mg or FOSAVANCE (70 mg/2800 IU) for 15-week base study followed by FOSAVANCE (70 mg/2800 IU) and placebo for the additional vitamin D<sub>3</sub> for 24-week extension study.

## 12.3 Pharmacokinetics

### Absorption

#### Alendronate Sodium

Relative to an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast. Oral bioavailability of the 10-mg tablet in men (0.59%) was similar to that in women when administered after an overnight fast and 2 hours before breakfast.

In a study, the alendronate in the FOSAVANCE 70 mg/5600 IU tablets was found to be equally bioavailable to the alendronate in the FOSALAN (alendronate sodium) 70-mg tablets.

A study examining the effect of timing of a meal on the bioavailability of alendronate was performed in 49 postmenopausal women. Bioavailability was decreased (by approximately 40%) when 10 mg alendronate was administered either 0.5 or 1 hour before a standardized breakfast, when compared to dosing 2 hours before eating. In studies of treatment and prevention of osteoporosis, alendronate was effective when administered at least 30 minutes before breakfast.

Bioavailability was negligible whether alendronate was administered with or up to two hours after a standardized breakfast. Concomitant administration of alendronate with coffee or orange juice reduced bioavailability by approximately 60%.

#### Cholecalciferol

Following administration of FOSAVANCE 70 mg/5600 IU Tablets after an overnight fast and two hours before a standard meal, the baseline adjusted mean area under the serum-concentration-time curve (AUC<sub>0-80 hrs</sub>) and baseline adjusted mean maximal serum concentration (C<sub>max</sub>) for vitamin D<sub>3</sub> were 355.6 ng-hr/mL and 10.8 ng/mL, respectively. The baseline adjusted mean time to maximal serum concentration (T<sub>max</sub>) was 9.2 hrs. The bioavailability of the 5600 IU vitamin D<sub>3</sub> in the FOSAVANCE 70 MG/ 5600 IU TABLETS is similar to 5600 IU vitamin D<sub>3</sub> administered as two 2800 IU vitamin D<sub>3</sub> tablets.



### *Distribution*

#### *Alendronate Sodium*

Preclinical studies (in male rats) show that alendronate transiently distributes to soft tissues following 1 mg/kg intravenous administration but is then rapidly redistributed to bone or excreted in the urine. The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans. Concentrations of drug in plasma following therapeutic oral doses are too low (less than 5 ng/mL) for analytical detection. Protein binding in human plasma is approximately 78%.

#### *Cholecalciferol*

Following absorption, vitamin D<sub>3</sub> enters the blood as part of chylomicrons. Vitamin D<sub>3</sub> is rapidly distributed mostly to the liver where it undergoes metabolism to 25-hydroxyvitamin D<sub>3</sub>, the major storage form. Lesser amounts are distributed to adipose tissue and stored as vitamin D<sub>3</sub> at these sites for later release into the circulation. Circulating vitamin D<sub>3</sub> is bound to vitamin D-binding protein.

### *Metabolism*

#### *Alendronate Sodium*

There is no evidence that alendronate is metabolized in animals or humans.

#### *Cholecalciferol*

Vitamin D<sub>3</sub> is rapidly metabolized by hydroxylation in the liver to 25-hydroxyvitamin D<sub>3</sub>, and subsequently metabolized in the kidney to 1,25-dihydroxyvitamin D<sub>3</sub>, which represents the biologically active form. Further hydroxylation occurs prior to elimination. A small percentage of vitamin D<sub>3</sub> undergoes glucuronidation prior to elimination.

### *Excretion*

#### *Alendronate Sodium*

Following a single intravenous dose of [<sup>14</sup>C]alendronate, approximately 50% of the radioactivity was excreted in the urine within 72 hours and little or no radioactivity was recovered in the feces. Following a single 10-mg intravenous dose, the renal clearance of alendronate was 71 mL/min (64, 78; 90% confidence interval [CI]), and systemic clearance did not exceed 200 mL/min. Plasma concentrations fell by more than 95% within 6 hours following intravenous administration. The terminal half-life in humans is estimated to exceed 10 years, probably reflecting release of alendronate from the skeleton. Based on the above, it is estimated that after 10 years of oral treatment with FOSALAN (10 mg daily) the amount of alendronate released daily from the skeleton is approximately 25% of that absorbed from the gastrointestinal tract.

#### *Cholecalciferol*

When radioactive vitamin D<sub>3</sub> was intravenously administered to healthy subjects, the mean urinary excretion of radioactivity after 48 hours was 2.4% of the administered dose, and the mean fecal excretion of radioactivity after 48 hours was 4.9% of the administered dose. In both cases, the excreted radioactivity was almost exclusively as metabolites of the parent. The mean half-life of baseline adjusted vitamin D<sub>3</sub> in the serum following an oral dose of FOSAVANCE 70 MG/ 5600 IU TABLETS is approximately 14 hours.

#### *Specific Populations*

*Gender:* Bioavailability and the fraction of an intravenous dose of alendronate excreted in urine were similar in men and women.

#### *Geriatric:*

##### *Alendronate Sodium*

Bioavailability and disposition of alendronate (urinary excretion) were similar in elderly and younger patients. No dosage adjustment of alendronate is necessary.

##### *Cholecalciferol*

Dietary requirements of vitamin D<sub>3</sub> are increased in the elderly.

*Race:* Pharmacokinetic differences due to race have not been studied.

#### *Renal Impairment:*

##### *Alendronate Sodium*

Preclinical studies show that, in rats with kidney failure, increasing amounts of drug are present in plasma, kidney, spleen, and tibia. In healthy controls, drug that is not deposited in bone is rapidly excreted in the urine. No evidence of saturation of bone uptake was found after 3 weeks dosing with cumulative intravenous doses of 35 mg/kg in young male rats. Although no formal renal impairment pharmacokinetic study has been conducted in patients, it is likely that, as in animals, elimination of

alendronate via the kidney will be reduced in patients with impaired renal function. Therefore, somewhat greater accumulation of alendronate in bone might be expected in patients with impaired renal function.

No dosage adjustment is necessary for patients with creatinine clearance 35 to 60 mL/min. FOSAVANCE 70 MG/ 5600 IU TABLETS are not recommended for patients with creatinine clearance less than 35 mL/min due to lack of experience with alendronate in renal failure.

*Cholecalciferol*

Patients with renal insufficiency will have decreased ability to form the active 1,25-dihydroxyvitamin D<sub>3</sub> metabolite.

*Hepatic Impairment:*

*Alendronate Sodium*

As there is evidence that alendronate is not metabolized or excreted in the bile, no studies were conducted in patients with hepatic impairment. No dosage adjustment is necessary.

*Cholecalciferol*

Vitamin D<sub>3</sub> may not be adequately absorbed in patients who have malabsorption due to inadequate bile production.

*Drug Interactions*

*Alendronate Sodium*

Intravenous ranitidine was shown to double the bioavailability of oral alendronate. The clinical significance of this increased bioavailability and whether similar increases will occur in patients given oral H<sub>2</sub>-antagonists is unknown.

In healthy subjects, oral prednisone (20 mg three times daily for five days) did not produce a clinically meaningful change in the oral bioavailability of alendronate (a mean increase ranging from 20 to 44%).

Products containing calcium and other multivalent cations are likely to interfere with absorption of alendronate.

*Cholecalciferol*

Olestra, mineral oils, orlistat, and bile acid sequestrants (e.g., cholestyramine, colestipol) may impair the absorption of vitamin D. Anticonvulsants, cimetidine, and thiazides may increase the catabolism of vitamin D.

### 13 NONCLINICAL TOXICOLOGY

#### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

The following data are based on findings for the individual components of FOSAVANCE 70 MG/ 5600 IU TABLETS.

*Alendronate Sodium*

Harderian gland (a retro-orbital gland not present in humans) adenomas were increased in high-dose female mice (p=0.003) in a 92-week oral carcinogenicity study at doses of alendronate of 1, 3, and 10 mg/kg/day (males) or 1, 2, and 5 mg/kg/day (females). These doses are equivalent to 0.5 to 4 times the highest recommended clinical daily dose of 10 mg based on surface area, mg/m<sup>2</sup>. The relevance of this finding to humans is unknown.

Parafollicular cell (thyroid) adenomas were increased in high-dose male rats (p=0.003) in a 2-year oral carcinogenicity study at doses of 1 and 3.75 mg/kg body weight. These doses are equivalent to 1 and 4 times the 10-mg clinical daily dose based on surface area, mg/m<sup>2</sup>. The relevance of this finding to humans is unknown.

Alendronate was not genotoxic in the *in vitro* microbial mutagenesis assay with and without metabolic activation, in an *in vitro* mammalian cell mutagenesis assay, in an *in vitro* alkaline elution assay in rat hepatocytes, and in an *in vivo* chromosomal aberration assay in mice. In an *in vitro* chromosomal aberration assay in Chinese hamster ovary cells, however, alendronate gave equivocal results.

Alendronate had no effect on fertility (male or female) in rats at oral doses up to 5 mg/kg/day (4 times the 10-mg clinical daily dose based on surface area, mg/m<sup>2</sup>).

*Cholecalciferol*

The carcinogenic potential of cholecalciferol (vitamin D<sub>3</sub>) has not been studied in rodents. Calcitriol, the hormonal metabolite of cholecalciferol, was not genotoxic in the Ames microbial mutagenesis assay with or without metabolic activation, and in an *in vivo* micronucleus assay in mice.

Ergocalciferol (vitamin D<sub>2</sub>) at high doses (150,000 to 200,000 IU/kg/day) administered prior to mating resulted in altered estrous cycle and inhibition of pregnancy in rats. The potential effect of cholecalciferol on male fertility is unknown in rats.

### **13.2 Animal Toxicology and/or Pharmacology**

The relative inhibitory activities on bone resorption and mineralization of alendronate and etidronate were compared in the Schenk assay, which is based on histological examination of the epiphyses of growing rats. In this assay, the lowest dose of alendronate that interfered with bone mineralization (leading to osteomalacia) was 6000-fold the antiresorptive dose. The corresponding ratio for etidronate was one to one. These data suggest that alendronate administered in therapeutic doses is highly unlikely to induce osteomalacia.

## **14 CLINICAL STUDIES**

### **14.1 Treatment of Osteoporosis in Postmenopausal Women**

#### *FOSALAN Daily*

The efficacy of FOSALAN 10 mg daily was assessed in four clinical trials. Study 1, a three-year, multicenter, double-blind, placebo-controlled, US clinical study enrolled 478 patients with a BMD T-score at or below minus 2.5 with or without a prior vertebral fracture; Study 2, a three-year, multicenter, double-blind, placebo-controlled, Multinational clinical study enrolled 516 patients with a BMD T-score at or below minus 2.5 with or without a prior vertebral fracture; Study 3, the Three-Year Study of the Fracture Intervention Trial (FIT), a study which enrolled 2027 postmenopausal patients with at least one baseline vertebral fracture; and Study 4, the Four-Year Study of FIT, a study which enrolled 4432 postmenopausal patients with low bone mass but without a baseline vertebral fracture.

#### *Effect on Fracture Incidence*

To assess the effects of FOSALAN on the incidence of vertebral fractures (detected by digitized radiography; approximately one third of these were clinically symptomatic), the U.S. and Multinational studies were combined in an analysis that compared placebo to the pooled dosage groups of FOSALAN (5 or 10 mg for three years or 20 mg for two years followed by 5 mg for one year). There was a statistically significant reduction in the proportion of patients treated with FOSALAN experiencing one or more new vertebral fractures relative to those treated with placebo (3.2% vs. 6.2%; a 48% relative risk reduction). A reduction in the total number of new vertebral fractures (4.2 vs. 11.3 per 100 patients) was also observed. In the pooled analysis, patients who received FOSALAN had a loss in stature that was statistically significantly less than was observed in those who received placebo (-3.0 mm vs. -4.6 mm).

The Fracture Intervention Trial (FIT) consisted of two studies in postmenopausal women: the Three-Year Study of patients who had at least one baseline radiographic vertebral fracture and the Four-Year Study of patients with low bone mass but without a baseline vertebral fracture. In both studies of FIT, 96% of randomized patients completed the studies (i.e., had a closeout visit at the scheduled end of the study); approximately 80% of patients were still taking study medication upon completion.

#### *Fracture Intervention Trial: Three-Year Study (patients with at least one baseline radiographic vertebral fracture)*

This randomized, double-blind, placebo-controlled, 2027-patient study (FOSALAN, n=1022; placebo, n=1005) demonstrated that treatment with FOSALAN resulted in statistically significant reductions in fracture incidence at three years as shown in Table 6.

Table 6: Effect of FOSALAN on Fracture Incidence in the Three-Year Study of FIT  
(patients with vertebral fracture at baseline)

	Percent of Patients		Absolute Reduction in Fracture Incidence	Relative Reduction in Fracture Risk %
	FOSALAN (n=1022)	Placebo (n=1005)		
Patients with:				
Vertebral fractures (diagnosed by X-ray) <sup>†</sup>				
≥1 new vertebral fracture	7.9	15.0	7.1	47 <sup>†</sup>
≥2 new vertebral fractures	0.5	4.9	4.4	90 <sup>†</sup>
Clinical (symptomatic) fractures				
Any clinical (symptomatic) fracture	13.8	18.1	4.3	26 <sup>‡</sup>
≥1 clinical (symptomatic) vertebral fracture	2.3	5.0	2.7	54 <sup>§</sup>
Hip fracture	1.1	2.2	1.1	51 <sup>¶</sup>
Wrist (forearm) fracture	2.2	4.1	1.9	48 <sup>¶</sup>


<sup>†</sup>Number evaluable for vertebral fractures: FOSALAN, n=984; placebo, n=966

<sup>‡</sup>p<0.001, <sup>§</sup>p=0.007, <sup>¶</sup>p<0.01, <sup>¶</sup>p<0.05

Furthermore, in this population of patients with baseline vertebral fracture, treatment with FOSALAN significantly reduced the incidence of hospitalizations (25.0% vs. 30.7%).

In the Three-Year Study of FIT, fractures of the hip occurred in 22 (2.2%) of 1005 patients on placebo and 11 (1.1%) of 1022 patients on FOSALAN, p=0.047. Figure 1 displays the cumulative incidence of hip fractures in this study.

Figure 1: Cumulative Incidence of Hip Fractures in the Three-Year Study of FIT (patients with radiographic vertebral fracture at baseline)



**Fracture Intervention Trial: Four-Year Study (patients with low bone mass but without a baseline radiographic vertebral fracture)**

This randomized, double-blind, placebo-controlled, 4432-patient study (FOSALAN, n=2214; placebo, n=2218) further investigated the reduction in fracture incidence due to FOSALAN. The intent of the study was to recruit women with osteoporosis, defined as a baseline femoral neck BMD at least two standard deviations below the mean for young adult women. However, due to subsequent revisions to the normative values for femoral neck BMD, 31% of patients were found not to meet this entry criterion and thus this study included both osteoporotic and non-osteoporotic women. The results are shown in Table 7 below for the patients with osteoporosis.

Table 7: Effect of FOSALAN on Fracture Incidence in Osteoporotic<sup>†</sup> Patients in the Four-Year Study of FIT  
(patients without vertebral fracture at baseline)

	Percent of Patients		Absolute Reduction in Fracture Incidence	Relative Reduction in Fracture Risk (%)
	FOSALAN (n=1545)	Placebo (n=1521)		
Patients with:				
Vertebral fractures (diagnosed by X-ray) <sup>†</sup>				
≥1 new vertebral fracture	2.5	4.8	2.3	48 <sup>‡</sup>
≥2 new vertebral fractures	0.1	0.6	0.5	78 <sup>§</sup>
Clinical (symptomatic) fractures				
Any clinical (symptomatic) fracture	12.9	16.2	3.3	22 <sup>¶</sup>
≥1 clinical (symptomatic) vertebral fracture	1.0	1.6	0.6	41 (NS) <sup>#</sup>
Hip fracture	1.0	1.4	0.4	29 (NS) <sup>#</sup>
Wrist (forearm) fracture	3.9	3.8	-0.1	NS <sup>#</sup>

<sup>†</sup>Baseline femoral neck BMD at least 2 SD below the mean for young adult women

<sup>‡</sup>Number evaluable for vertebral fractures: FOSALAN, n=1426; placebo, n=1428

<sup>§</sup>p<0.001, <sup>¶</sup>p=0.035, <sup>#</sup>p=0.01

<sup>#</sup>Not significant. This study was not powered to detect differences at these sites.

### Fracture Results Across Studies

In the Three-Year Study of FIT, FOSALAN reduced the percentage of women experiencing at least one new radiographic vertebral fracture from 15.0% to 7.9% (47% relative risk reduction, p<0.001); in the Four-Year Study of FIT, the percentage was reduced from 3.8% to 2.1% (44% relative risk reduction, p=0.001); and in the combined U.S./Multinational studies, from 6.2% to 3.2% (48% relative risk reduction, p=0.034).

FOSALAN reduced the percentage of women experiencing multiple (two or more) new vertebral fractures from 4.2% to 0.6% (87% relative risk reduction, p<0.001) in the combined U.S./Multinational studies and from 4.9% to 0.5% (90% relative risk reduction, p<0.001) in the Three-Year Study of FIT. In the Four-Year Study of FIT, FOSALAN reduced the percentage of osteoporotic women experiencing multiple vertebral fractures from 0.6% to 0.1% (78% relative risk reduction, p=0.035).

Thus, FOSALAN reduced the incidence of radiographic vertebral fractures in osteoporotic women whether or not they had a previous radiographic vertebral fracture.

### Effect on Bone Mineral Density


The bone mineral density efficacy of FOSALAN 10 mg once daily in postmenopausal women, 44 to 84 years of age, with osteoporosis (lumbar spine bone mineral density [BMD] of at least 2 standard deviations below the premenopausal mean) was demonstrated in four double-blind, placebo-controlled clinical studies of two or three years' duration.

Figure 2 shows the mean increases in BMD of the lumbar spine, femoral neck, and trochanter in patients receiving FOSALAN 10 mg/day relative to placebo-treated patients at three years for each of these studies.



Figure 2:


**Osteoporosis Treatment Studies in Postmenopausal Women**  
**Increase in BMD**  
**Alendronate Sodium 10 mg/day at Three Years**



At three years significant increases in BMD, relative both to baseline and placebo, were seen at each measurement site in each study in patients who received FOSALAN 10 mg/day. Total body BMD also increased significantly in each study, suggesting that the increases in bone mass of the spine and hip did not occur at the expense of other skeletal sites. Increases in BMD were evident as early as three months and continued throughout the three years of treatment. (See figure 3 for lumbar spine results.) In the two-year extension of these studies, treatment of 147 patients with FOSALAN 10 mg/day resulted in continued increases in BMD at the lumbar spine and trochanter (absolute additional increases between years 3 and 5: lumbar spine, 0.94%; trochanter, 0.88%). BMD at the femoral neck, forearm and total body were maintained. FOSALAN was similarly effective regardless of age, race, baseline rate of bone turnover, and baseline BMD in the range studied (at least 2 standard deviations below the premenopausal mean).

Figure 3:

**Osteoporosis Treatment Studies in Postmenopausal Women**  
**Time Course of Effect of Alendronate Sodium 10 mg/day Versus Placebo:**  
**Lumbar Spine BMD Percent Change From Baseline**



In patients with postmenopausal osteoporosis treated with FOSALAN 10 mg/day for one or two years, the effects of treatment withdrawal were assessed. Following discontinuation, there were no further increases in bone mass and the rates of bone loss were similar to those of the placebo groups.

#### *Bone Histology*

Bone histology in 270 postmenopausal patients with osteoporosis treated with FOSALAN at doses ranging from 1 to 20 mg/day for one, two, or three years revealed normal mineralization and structure, as well as the expected decrease in bone turnover relative to placebo. These data, together with the normal bone histology and increased bone strength observed in rats and baboons exposed to long-term alendronate treatment, support the conclusion that bone formed during therapy with FOSALAN is of normal quality.

#### *Effect on Height*

FOSALAN, over a three- or four-year period, was associated with statistically significant reductions in loss of height vs. placebo in patients with and without baseline radiographic vertebral fractures. At the end of the FIT studies, the between-treatment group differences were 3.2 mm in the Three-Year Study and 1.3 mm in the Four-Year Study.

#### *FOSALAN Once-Weekly*

The therapeutic equivalence of FOSALAN Once-Weekly 70 mg (n=519) and FOSALAN 10 mg daily (n=370) was demonstrated in a one-year, double-blind, multicenter study of postmenopausal women with osteoporosis. In the primary analysis of completers, the mean increases from baseline in lumbar spine BMD at one year were 5.1% (4.8, 5.4%; 95% CI) in the 70-mg once-weekly group (n=440) and 5.4% (5.0, 5.8%; 95% CI) in the 10-mg daily group (n=330). The two treatment groups were also similar with regard to BMD increases at other skeletal sites. The results of the intention-to-treat analysis were consistent with the primary analysis of completers.

#### *Concomitant Use with Estrogen Hormone Replacement Therapy*

The effects on BMD of treatment with FOSALAN 10 mg once daily and conjugated estrogen (0.625 mg/day) either alone or in combination were assessed in a two-year, double-blind, placebo-controlled study of hysterectomized postmenopausal osteoporotic women (n=425). At two years, the increases in lumbar spine BMD from baseline were significantly greater with the combination (8.3%) than with either estrogen or FOSALAN alone (both 6.0%).

The effects on BMD when FOSALAN was added to stable doses (for at least one year) of HRT (estrogen ± progestin) were assessed in a one-year, double-blind, placebo-controlled study in postmenopausal osteoporotic women (n=428). The addition of FOSALAN 10 mg once daily to HRT produced, at one year, significantly greater increases in lumbar spine BMD (3.7%) vs. HRT alone (1.1%).

In these studies, significant increases or favorable trends in BMD for combined therapy compared with HRT alone were seen at the total hip, femoral neck, and trochanter. No significant effect was seen for total body BMD.

Histomorphometric studies of transiliac biopsies in 92 subjects showed normal bone architecture. Compared to placebo there was a 98% suppression of bone turnover (as assessed by mineralizing surface) after 18 months of combined treatment with FOSALAN and HRT, 94% on FOSALAN alone, and 78% on HRT alone. The long-term effects of combined FOSALAN and HRT on fracture occurrence and fracture healing have not been studied.

### **14.2 Treatment to Increase Bone Mass in Men with Osteoporosis**

The efficacy of FOSALAN in men with hypogonadal or idiopathic osteoporosis was demonstrated in two clinical studies.

#### *FOSALAN Daily*

A two-year, double-blind, placebo-controlled, multicenter study of FOSALAN 10 mg once daily enrolled a total of 241 men between the ages of 31 and 87 (mean, 63). All patients in the trial had either a BMD T-score less than or equal to -2 at the femoral neck and less than or equal to -1 at the lumbar spine, or a baseline osteoporotic fracture and a BMD T-score less than or equal to -1 at the femoral neck. At two years, the mean increases relative to placebo in BMD in men receiving FOSALAN 10 mg/day were significant at the following sites: lumbar spine, 5.3%; femoral neck, 2.6%; trochanter, 3.1%; and total body, 1.6%. Treatment with FOSALAN also reduced height loss (FOSALAN, -0.6 mm vs. placebo, -2.4 mm).

#### *FOSALAN Once-Weekly*

A one-year, double-blind, placebo-controlled, multicenter study of once weekly FOSALAN 70 mg enrolled a total of 167 men between the ages of 38 and 91 (mean, 66). Patients in the study had either a

BMD T-score less than or equal to -2 at the femoral neck and less than or equal to -1 at the lumbar spine, or a BMD T-score less than or equal to -2 at the lumbar spine and less than or equal to -1 at the femoral neck, or a baseline osteoporotic fracture and a BMD T-score less than or equal to -1 at the femoral neck. At one year, the mean increases relative to placebo in BMD in men receiving FOSALAN 70 mg once weekly were significant at the following sites: lumbar spine, 2.8%; femoral neck, 1.9%; trochanter, 2.0%; and total body, 1.2%. These increases in BMD were similar to those seen at one year in the 10 mg once-daily study.

In both studies, BMD responses were similar regardless of age (greater than or equal to 65 years vs. less than 65 years), gonadal function (baseline testosterone less than 9 ng/dL vs. greater than or equal to 9 ng/dL), or baseline BMD (femoral neck and lumbar spine T-score less than or equal to -2.5 vs. greater than -2.5).

## **16 HOW SUPPLIED/STORAGE AND HANDLING**

### *Shelf life*

The expiry date of the product is indicated on the packaging materials.

FOSAVANCE 70 mg/5600 IU Tablets are white to off-white, modified rectangular shaped tablets with "270" on one side and a bone shape on the other side.

They are supplied as follows:

Unit of use blister packages of 2, 4

### *Storage*

Store at 20-25°C. Store tablets in the original blister package in order to protect from moisture and light.

**Manufacturer:** Organon LLC, NJ USA

**License holder and address:** Organon Pharma Israel Ltd., 1 Atir Yeda, Kfar Saba

**Drug registration no. listed in the official Registry of the Ministry of Health:** 140-99-31792

Revised in March 2022.